NGF has been shown in preclinical studies to mediate tumor nerve growth and has subsequently been targeted in clinical trials in prostate cancer via a small-molecule inhibitor of the NGF cognate receptor TRKA (Collins et al., 2007; Zahalka and Frenette, 2020). This evidence concerns the gene NTRK1 and Familial prostate cancer.